Sökning: onr:"swepub:oai:DiVA.org:oru-74048" >
Effects of n-3 FA s...
Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells : the OmegAD study
-
- Wang, Xiuzhe (författare)
- Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Stockholm, Sweden; Department of Neurology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
-
- Hjorth, Erik (författare)
- Karolinska Institutet
-
- Vedin, Inger (författare)
- Karolinska Institutet
-
visa fler...
-
- Eriksdotter, Maria (författare)
- Karolinska Institutet
-
- Freund-Levi, Yvonne, 1956- (författare)
- Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Stockholm, Sweden
-
- Wahlund, Lars-Olof (författare)
- Karolinska Institutet
-
- Cederholm, Tommy (författare)
- Karolinska Institutet,Uppsala universitet,Klinisk nutrition och metabolism
-
- Palmblad, Jan (författare)
- Karolinska Institutet
-
- Schultzberg, Marianne (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- American Society for Biochemistry and Molecular Biology, 2015
- 2015
- Engelska.
-
Ingår i: Journal of Lipid Research. - : American Society for Biochemistry and Molecular Biology. - 0022-2275 .- 1539-7262. ; 56:3, s. 674-681
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Specialized proresolving mediators (SPMs) induce resolution of inflammation. SPMs are derivatives of n-3 and n-6 PUFAs and may mediate their beneficial effects. It is unknown whether supplementation with PUFAs influences the production of SPMs. Alzheimer's disease (AD) is associated with brain inflammation and reduced levels of SPMs. The OmegAD study is a randomized, double-blind, and placebo-controlled clinical trial on AD patients, in which placebo or a supplement of 1.7 g DHA and 0.6 g EPA was taken daily for 6 months. Plasma levels of arachidonic acid decreased, and DHA and EPA levels increased after 6 months of n-3 FA treatment. Peripheral blood mononuclear cells (PBMCs) were obtained before and after the trial. Analysis of the culture medium of PBMCs incubated with amyloid-β 1-40 showed unchanged levels of the SPMs lipoxin A4 and resolvin D1 in the group supplemented with n-3 FAs, whereas a decrease was seen in the placebo group. The changes in SPMs showed correspondence to cognitive changes. Changes in the levels of SPMs were positively correlated to changes in transthyretin. We conclude that supplementation with n-3 PUFAs for 6 months prevented a reduction in SPMs released from PBMCs of AD patients, which was associated with changes in cognitive function.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinsk bioteknologi -- Medicinsk bioteknologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Medical Biotechnology -- Medical Biotechnology (hsv//eng)
Nyckelord
- Alzheimer’s disease
- amyloid β
- clinical trials
- docosahexaenoic acid
- fatty acid
- fish oil
- inflammation
- lipoxin
- nutrition
- peripheral blood mononuclear cell
- resolvin
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas